|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Datamonitor, Dec 2010, Pages: 416
Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
The non-insulins antidiabetics market is forecast to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists are driving pipeline growth, and the first launch of the novel SGLT-2 inhibitor class is also forecast.
Scope of this research
- Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes.
- A detailed clinical and commercial assessment of all key emerging therapies.
- Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2019.
- Analysis of unmet needs in non-insulin diabetes therapies and key development R&D strategies in light of regulatory changes.
Research and analysis highlights
- A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 179 candidates are in clinical trials, and 16 Big Pharma companies are engaged in diabetes drug development.
- GLP-1 agonists are likely to be the most successful pipeline candidates, and the class pipeline is forecast to generate sales of $3.7 billion in the seven major markets in 2019. Once-weekly Bydureon is forecast to be the class leader, despite FDA requirements for a new trial.
- DPP-4 inhibitors will continue to grow driven by new combinations of marketed molecules. The launch of SGLT-2 inhibitors will provide another option in a crowded treatment algorithm for type 2 diabetes.
Key reasons to purchase this research
- Quantify the sales of pipeline drugs in the non-insulin antidiabetic market.
- Identify licensing opportunities based on company portfolio and market needs.
- Assess the remaining market opportunities and barriers to uptake for novel antidiabetic therapies.
|
|
|
|
